Vaccine trends: a narrative review.
Level 5 - mechanism / opinion, no new human data
Narrative review without systematic search or original human data
PubMed 41199607 · doi:10.12701/jyms.2025.42.71
What was done
The authors conducted a narrative review summarizing the historical shift in infectious disease frameworks toward One Health, developments in vaccine platforms (mRNA, DNA, viral vectors, and nanoparticles), applications to noncommunicable diseases, and persistent public health challenges.
What was found
The abstract reports no quantitative results, statistical analyses, or empirical effect estimates. It qualitatively describes advances in personalized vaccinomics, applications targeting cancer and Alzheimer disease, and challenges including pathogen evolution, waning immunity, vaccine hesitancy, and access inequities.
Why it matters
It provides a broad, high-level summary of contemporary vaccine platform innovations and emphasizes the structural and logistical requirements needed to address future pandemic threats.
Limits
This is an unsystematic narrative overview without documented search criteria, study selection protocols, quality appraisal, or quantitative synthesis. No original empirical data are presented.
Cited by
- supports Mayo Clinic leads the field of vaccinomics, studying how genetic and immune differences affect individual responses to vaccines.